Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available

Autor:	Gianmatteo Pica, Enrique Báez de la Fuente, Jan Van Droogenbroeck, Sorin Visanica, Brian Leber, Timothy Devos, Hacene Zerazhi, Antonio Almeida, Albert Kandra, Linda Chrit, Jean-Jacques Kiladjian, Dana Ranta, Juliane Morando, Lynda Foltz
Rok vydání:	2019
Předmět:	Adult Male Oncology Cancer Research Ruxolitinib medicine.medical_specialty Treatment protocol Antineoplastic Agents 03 medical and health sciences 0302 clinical medicine Polycythemia vera hemic and lymphatic diseases Internal medicine Nitriles Humans Hydroxyurea Medicine Polycythemia Vera Aged Aged 80 and over Salvage Therapy business.industry Hematology Middle Aged Prognosis medicine.disease Survival Rate Pyrimidines Drug Resistance Neoplasm 030220 oncology & carcinogenesis Pyrazoles Female Open label business Follow-Up Studies 030215 immunology medicine.drug
Zdroj:	Leukemia & Lymphoma. 60:3493-3502
ISSN:	1029-2403 1042-8194
Popis:	Ruxolitinib was recently approved for the treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea based on data from the RESPONSE studies. This phase 3b, Expanded Treatment Protocol study (NCT02292446) of ruxolitinib for hydroxyurea-resistant/intolerant patients with polycythemia vera (
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f605dfd5993e44330daad2fab631c2d6 https://doi.org/10.1080/10428194.2019.1636985 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.